Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease

Kay Cheong Teo; Shu-Leong Ho

首页> 中文期刊> 《转化神经变性病(英文)》 >Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease

Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

There is a substantial amount of evidence from experimental parkinsonian models to show the neuroprotective effects of monoamine oxidase-B(MAOB)inhibitors.They have been studied for their potential disease-modifying effects in Parkinson’s disease(PD)for over 20 years in various clinical trials.This review provides a summary of the clinical trials and discusses the implications of their results in the context of disease-modification in PD.Earlier clinical trials on selegiline were confounded by symptomatic effects of this drug.Later clinical trials on rasagiline using delayed-start design provide newer insights in disease-modification in PD but success in achieving the aims of this strategy remain elusive due to obstacles,some of which may be insurmountable.

著录项

来源
《转化神经变性病(英文)》 |2013年第1期|P.124-133|共10页
作者
Kay Cheong Teo; Shu-Leong Ho;
展开▼
作者单位

Division of Neurology Department of Medicine University of Hong Kong Hong Kong China;

Division of Neurology Department of Medicine University of Hong Kong Hong Kong ChinaResearch Centre of Heart Brain Hormone and Healthy Aging(HBHA) University of Hong Kong Hong Kong China;

展开▼
原文格式 PDF
正文语种 chi
中图分类神经病学与精神病学;
关键词
Parkinson''s disease; Monoamine oxidase-B inhibitors; Disease-modification; Neuroprotection; Selegiline; Rasagiline;

Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease

摘要

著录项

相关主题

期刊订阅